Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Business Insights | Biotech M&A Strategies: Deal assessments, trends and future prospects

Biotech M&A Strategies: Deal assessments, trends and future prospects

M&A activity in the pharma industry continues to gain momentum as a growing number of companies seek to replenish drug pipelines through biotechnology acquisitions. M&As between biotech companies are also growing in number, stimulated by the drive to strengthen product portfolios and expand participation in the growing global biotech market. Such deal activity is expected to become an increasingly prominent feature in the biotech sector over the next few years. Over 68% of respondents to Business Insights' recent proprietary survey carried out for this report believe that M&A initiatives will be integral to the continued success of their company. ‘Biotech M&A Trends: Deal assessments, trends and future prospects’ is a new report published by Business Insights that analyses trends in biotech M&A deals valued below $1bn across mid/small-sized pharma and biotech companies, including niche biopharma players and diagnostics/medical technology businesses. Trends in the value, volume and geographical distribution of deals are examined based on M&A activity since 2003 and a proprietary Business Insights survey reveals how over 130 industry executives perceive the future of biotech M&As. This report identifies the key factors influencing transactions with an evaluation of over 50 recent deals, in addition to providing a comprehensive case study analysis detailing the strategies behind five major M&A’s.

Published: October 2008 - Global. PDF

Table of Contents
Price: $3,835.00 / €2,563.31

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions